COMPANY OVERVIEW
Organovo, headquartered in San Diego, California, pioneered commercial bioprinting of functional human tissues. Founded in 2007, the company developed the NovoGen bioprinting platform to create 3D tissue constructs with organized architecture mimicking native organs, initially for drug discovery applications and advancing toward therapeutic tissue implants.
TECHNOLOGY PLATFORM
- NovoGen Bioprinter: Extrusion-based bioprinting with cellular bio-inks
- ExVive Liver: Bioprinted liver tissue with hepatocytes, stellate, and endothelial cells
- ExVive Kidney: Proximal tubule models for nephrotoxicity assessment
- Architectural Control: Spatially organized multicellular tissues with vascular channels
- Long-Term Function: Metabolic activity maintained 28+ days
KEY APPLICATIONS
- Drug-induced liver injury (DILI) prediction with multicellular architecture
- Fibrosis modeling with stellate cell activation in 3D context
- Nephrotoxicity screening with functional tubular structures
- Therapeutic tissue patches for liver disease (development stage)
- Custom tissue fabrication for pharmaceutical partners
STRATEGIC EVOLUTION
Organovo transitioned from a services model toward therapeutic tissue development, partnering with academic medical centers on implantable tissue programs. The company's bioprinting expertise positions it at the intersection of drug discovery tools and regenerative medicine applications.